Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Muscle strength · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 16 participantsLow
Findings
What do systematic reviews say?
26 questions · 26 findings · 3 reviews
No studies found 6 · 23.1%GRADE not reported 4 · 15.4%Very low 6 · 23.1%Low 7 · 26.9%Moderate 3 · 11.5%High 0 · 0%
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Change in quality of life · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 54 participantsVery low
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Change in pulmonary function · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 24 participantsLow
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 61 participantsModerate
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.32 [0.92, 1.89]1 study · 61 participantsModerate